Vesna Vetma*†‡, Jan Rožanc§, Emilie M. Charles*†, Christian T. Hellwig*†‡¶, Leonidas G. Alexopoulos§#, Markus Rehm*†‡#
Oncology Research, Vol.25, No.9, pp. 1489-1494, 2017, DOI:10.3727/096504017X14897145996933
Abstract Antagonists of inhibitors of apoptosis proteins (IAPs), alone or in combination with genotoxic therapeutics,
have been shown to efficiently induce cell death in various solid tumors. The IAP antagonist birinapant is
currently being tested in phase II clinical trials. We herein aimed to investigate the antitumor efficacy
of dacarbazine in vitro, both as a single agent and in combination with birinapant, in melanoma cell lines.
Covering clinically relevant drug concentration ranges, we conducted a total of 5,400 measurements in a panel
of 12 human melanoma cell lines representing different stages of disease progression. Surprisingly, functionally More >
Login
Register
